Drugs / PALUPIPRANT
PALUPIPRANT
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05358691 | Nov 2024 → Dec 2027 | lung carcinoma | Rutgers, The State University of New Jersey | Withdrawn | No outcome recorded |
| Phase 1 | NCT05191667 | Jan 2022 → Dec 2025 | esophageal cancer | Adlai Nortye Biopharma Co., Ltd. | Suspended | No outcome recorded |
| Phase 1 | NCT04975958 | Sep 2021 → Jan 2025 | — | Adlai Nortye Biopharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04432857 | Aug 2020 → May 2024 | cervical cancer, colorectal cancer, non-small cell lung carcinoma, triple-negative breast carcinoma +1 | Adlai Nortye Biopharma Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03152370 | May 2017 → Aug 2021 | — | Adlai Nortye Biopharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02540291 | Jul 2015 → Feb 2018 | neoplasm | Eisai Inc. | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PALUPIPRANT | ChEMBL registry synonym — accepted as the source's own label CHEMBL3670685 ↗ |
| Known as | AN0025 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05358691 ↗ |
| Known as | E7046 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02540291 ↗ |
| Known as | ER 886046 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3670685 ↗ |
| Action | Inhibit | “E7046 is a highly selective, small-molecule antagonist of the E-type prostanoid receptor 4 (EP4) for prostaglandin E2, an immunosuppressive mediator of the tumor immune...” PMID 32554609 ↗ Jun 2020 |
| Modality | Small molecule | “E7046 is a highly selective, small-molecule antagonist of the E-type prostanoid receptor 4 (EP4) for prostaglandin E2, an immunosuppressive mediator of the tumor immune...” PMID 32554609 ↗ Jun 2020 |
| Route | Oral | “E7046 was administered orally once-daily in sequential escalating dose cohorts (125, 250, 500, and 750 mg) with ≥6 patients per cohort.” PMID 32554609 ↗ Jun 2020 |